Hepatitis Therapeutics Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Jan 2019| TMR1292A| Transparency

Report Highlights

Global Hepatitis Therapeutics Market: Overview

This report analyzes the current and future scenario of the global hepatitis therapeutics market. Increase in the prevalence of viral hepatitis, promising hepatitis drug pipeline, and favorable government support are the major drivers of the global market.

The global hepatitis therapeutics market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to segments based on disease type, drug class, distribution channel, and region. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the overview section. Additionally, the section comprises company profiles with product portfolio to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis, by region, and market share analysis, by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global hepatitis therapeutics market.

Global Hepatitis Therapeutics Market: Key Segments

The global hepatitis therapeutics market has been segmented based on disease type, drug class, distribution channel, and region. In terms of disease type, the global market has been segmented into hepatitis A, hepatitis B, hepatitis C, and others. Based on drug class, the global hepatitis therapeutics market has been categorized into nucleotide analog reverse transcriptase inhibitor, NS5A inhibitor, multi- class combination, nucleotide analog NS5B polymerase inhibitor, interferon & ribavirin, and others. Based on distribution channel, the global market has been divided into hospital pharmacies, retail pharmacies, and others. The market value and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.

Global Hepatitis Therapeutics Market: Regional Outlook

The global hepatitis therapeutics market has been segmented into five major regions: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC Countries, South Africa, and Rest of Middle East & Africa). The Market Value and forecast for each of these regions and countries/sub-regions have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in Report

The report also profiles major players in the global hepatitis therapeutics market based on various attributes such as company overview, financial overview, product portfolio, business strategies, recent developments, and SWOT analysis. Major companies profiled in the report are Bristol Myers Squibb, Gilead Sciences, Inc., Merck & Co., Inc., F. Hoffmann-La Roche, Ltd., LAURUS Labs, AbbVie Inc., Hetero Healthcare Limited, Zydus Cadila, Cipla, Inc., and NATCO Pharma Limited.

The global hepatitis therapeutics market has been segmented as below:

Global Hepatitis Therapeutics Market, by Disease
Hepatitis A
Hepatitis B
Hepatitis C
Others
Global Hepatitis Therapeutics Market, by Drug Class
Nucleotide Analog Reverse Transcriptase Inhibitor
NS5A Inhibitor
Multi Class Combination
Nucleotide Analog NS5B Polymerase Inhibitor
Interferon & Ribavirin
Others
Global Hepatitis Therapeutics Market, by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Hepatitis Therapeutics Market, by Region
North America
U.S.
Canada
Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
Asia Pacific
India
China
Japan
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of Middle East & Africa

  • Table 1 : Pipeline Analysis
  • Table 2 : Pipeline Analysis
  • Table 3 : Pipeline Analysis
  • Table 4 : New Product Launch, Approvals & Patent Expiry
  • Table 5 : Global Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Disease Type, 2016 – 2026 2016–2026
  • Table 6 : Global Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016 – 2026
  • Table 7 : Global Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
  • Table 8 : Global Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Region, 2016–2026
  • Table 9 : North America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016 – 2026
  • Table 10 : North America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Disease Type, 2016 – 2026
  • Table 11 : North America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016 – 2026
  • Table 12 : North America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 – 2026
  • Table 13 : Europe Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016 – 2026
  • Table 14 : Europe Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Disease Type, 2016 – 2026
  • Table 15 : Europe Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016 – 2026
  • Table 16 : Europe Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 – 2026
  • Table 17 : Asia Pacific Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016 – 2026
  • Table 18 : Asia Pacific Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Disease Type, 2016 – 2026
  • Table 19 : Asia Pacific Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016 – 2026
  • Table 20 : Asia Pacific Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 – 2026
  • Table 21 : Latin America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016 – 2026
  • Table 22 : Latin America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Disease Type, 2016 – 2026
  • Table 23 : Latin America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016 – 2026
  • Table 24 : Latin America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 – 2026
  • Table 25 : Middle East & Africa Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016 – 2026
  • Table 26 : Middle East & Africa Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Disease Type, 2016 – 2026
  • Table 27 : Middle East & Africa Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016 – 2026
  • Table 28 : Middle East & Africa Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 – 2026
  • Figure 1 : Global Hepatitis Therapeutics Market Value (US$ Mn) Forecast, 2016–2026
  • Figure 2 : Global Hepatitis Therapeutics Market Value Share (%), by Disease Type (2017)
  • Figure 3 : Global Hepatitis Therapeutics Market Value Share (%), by Drug Class (2017)
  • Figure 4 : Global Hepatitis Therapeutics Market Value Share (%), by Distribution Channel (2017)
  • Figure 5 : Global Hepatitis Therapeutics Market Value Share (%), by Region (2017)
  • Figure 6 : Global Hepatitis Therapeutics Market Value Share (%), by Disease Type, 2018 and 2026
  • Figure 7 : Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hepatitis A, 2016–2026
  • Figure 8 : Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hepatitis B, 2016–2026
  • Figure 9 : Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hepatitis C, 2016–2026
  • Figure 10 : Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2016–2026
  • Figure 11 : Global Hepatitis Therapeutics Market Attractiveness,, by Disease Type, 2018–2026
  • Figure 12 : Global Hepatitis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2026
  • Figure 13 : Global Hepatitis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
  • Figure 14 : Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Nucleotide Analog Reverse Transcriptase Inhibitor, 2016–2026
  • Figure 15 : Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by NS5A Inhibitor, 2016–2026
  • Figure 16 : Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Multi-class Combination, 2016–2026
  • Figure 17 : Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Nucleotide Analog NS5B Polymerase Inhibitor, 2016–2026
  • Figure 18 : Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Interferon & Ribavirin, 2016–2026
  • Figure 19 : Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2016–2026
  • Figure 20 : Global Hepatitis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2026
  • Figure 21 : Global Hepatitis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
  • Figure 22 : Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2016–2026
  • Figure 23 : Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2016–2026
  • Figure 24 : Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2016–2026
  • Figure 25 : Global Hepatitis Therapeutics Market Value Share Analysis, by Region, 2018 and 2026
  • Figure 26 : Global Hepatitis Therapeutics Market Attractiveness Analysis, by Region, 2018–2026
  • Figure 27 : North America Hepatitis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
  • Figure 28 : North America Hepatitis Therapeutics Market Value Share Analysis, by Country, 2018 and 2026
  • Figure 29 : North America Hepatitis Therapeutics Market AttractivenessAnalysis, by Country, 2018–2026
  • Figure 30 : North America Hepatitis Therapeutics Market Value Share (%), by Disease Type, 2018 and 2026
  • Figure 31 : North America Hepatitis Therapeutics Market Attractiveness, by Disease Type, 2018–2026
  • Figure 32 : North America Hepatitis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2026
  • Figure 33 : North America Hepatitis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
  • Figure 34 : North America Hepatitis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2026
  • Figure 35 : North America Hepatitis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
  • Figure 36 : Europe Hepatitis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
  • Figure 37 : Europe Hepatitis Therapeutics Market Value Share Analysis, by Country, 2018 and 2026
  • Figure 38 : Europe Hepatitis Therapeutics Market Attractiveness Analysis, by Country, 2018–2026
  • Figure 39 : Europe Hepatitis Therapeutics Market Value Share (%), by Disease Type, 2018 and 2026
  • Figure 40 : Europe Hepatitis Therapeutics Market Attractiveness, by Disease Type, 2018–2026
  • Figure 41 : Europe Hepatitis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2026
  • Figure 42 : Europe Hepatitis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
  • Figure 43 : Europe Hepatitis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2026
  • Figure 44 : Europe Hepatitis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
  • Figure 45 : Asia Pacific Hepatitis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
  • Figure 46 : Asia Pacific Hepatitis Therapeutics Market Value Share Analysis, by Country, 2018 and 2026
  • Figure 47 : Asia Pacific Hepatitis Therapeutics Market Attractiveness Analysis, by Country, 2018–2026
  • Figure 48 : Asia Pacific Hepatitis Therapeutics Market Value Share (%), by Disease Type, 2018 and 2026
  • Figure 49 : Asia Pacific Hepatitis Therapeutics Market Attractiveness, by Disease Type, 2018–2026
  • Figure 50 : Asia Pacific Hepatitis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2026
  • Figure 51 : Asia Pacific Hepatitis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
  • Figure 52 : Asia Pacific Hepatitis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2026
  • Figure 53 : Asia Pacific Hepatitis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
  • Figure 54 : Latin America Hepatitis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
  • Figure 55 : Latin America Hepatitis Therapeutics Market Value Share Analysis, by Country, 2018 and 2026
  • Figure 56 : Latin America Hepatitis Therapeutics Market Attractiveness Analysis, by Country, 2018–2026
  • Figure 57 : Latin America Hepatitis Therapeutics Market Value Share (%), by Disease Type, 2018 and 2026
  • Figure 58 : Latin America Hepatitis Therapeutics Market Attractiveness, by Disease Type, 2018–2026
  • Figure 59 : Latin America Hepatitis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2026
  • Figure 60 : Latin America Hepatitis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
  • Figure 61 : Latin America Hepatitis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2026
  • Figure 62 : Latin America Hepatitis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
  • Figure 63 : Middle East & Africa Hepatitis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
  • Figure 64 : Middle East & Africa Hepatitis Therapeutics Market Value Share Analysis, by Country, 2018 and 2026
  • Figure 65 : Middle East & Africa Hepatitis Therapeutics Market Attractiveness Analysis, by Country, 2018–2026
  • Figure 66 : Middle East & Africa Hepatitis Therapeutics Market Value Share (%), by Disease Type, 2018 and 2026
  • Figure 67 : Middle East & Africa Hepatitis Therapeutics Market Attractiveness, by Disease Type, 2018–2026
  • Figure 68 : Middle East & Africa Hepatitis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2026
  • Figure 69 : Middle East & Africa Hepatitis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
  • Figure 70 : Middle East & Africa Hepatitis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2026
  • Figure 71 : Middle East & Africa Hepatitis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
  • Figure 72 : Global Hepatitis Therapeutics Market Share, by Company, 2017

Leaders in analytics, research and advisory services for Fortune 500 companies, scores of high potential startups, and financial institutions. Our success stories have proven why we are a prominent provider of a cutting-edge syndicated and customized research services. Leverage the best of our seasoned research analysts who had a keen interest and enviable expertise of almost 4 million hours in global, regional, and local market intelligence.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
RELATED REPORTS